Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors

Linda E. Lévesque; James M. Brophy; Bin Zhang

doi:10.1503/cmaj.051679

Submit a Response to This Article

Compose Response

Title *

References

Author Information

Contributors

First Name and Middle Initial *

First or given name, e.g. 'Peter'.

Last Name *

Your last, or family, name, e.g. 'MacMoody'.

Degrees

Email Address *

Your email address, e.g. higgs-boson@gmail.com

Occupation *

Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.

Affiliation *

Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.

Address

Your organization, institution's or residential address.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

"Risk" may be explained by efficacy
Andrew J Ashworth

Posted on: 16 May 2006

Posted on: (16 May 2006)
Page navigation anchor for "Risk" may be explained by efficacy
"Risk" may be explained by efficacy
Andrew J Ashworth
These findings are interesting but may reflect the superiority of ROFECOXIB over other agents as an analgesic and effective anti- inflammatory rather than any specific cardiotoxic effect. The peak of cardiac events in the second week of treatment might simply be related to increased activity of individuals whoe previous disease induced pain, reduced activity and therefore degraded physical fitness. With a half life of 24...
Show More

These findings are interesting but may reflect the superiority of ROFECOXIB over other agents as an analgesic and effective anti- inflammatory rather than any specific cardiotoxic effect. The peak of cardiac events in the second week of treatment might simply be related to increased activity of individuals whoe previous disease induced pain, reduced activity and therefore degraded physical fitness. With a half life of 24 hours, it takes six half lives (about a week) to reach steady state and therefore maximumum sustained efficacy. That the peak dropped back towards baseline after the second week would, on this interpretation, be explained by the improved cardiac fitness induced by a further week of increased physical activity.
Perhaps we should be careful about how well we treat longstanding arthritis in those who long to be more active again.
Had the same quantative observations been made for SILDANAFIL (Viagra) the authors' qualitative (and speculative) interpretation might have been different!
Conflict of Interest:
None declared
Show Less

Competing Interests: None declared.